For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination r ...

2. Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ ...

A review of studies on communication between the nervous and immune systems redefines the neuroimmune connectome with a focus on health and disease, and discusses how the latest techniques can ...

According to the Company, the decision followed an interim review of safety, PK, and efficacy data. Specifically, results ...

Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Will Nightingale, Reviews Editor The driving position in the Nissan Qashqai is superb. The driver's seat is comfy, and lines up well with the pedals and steering wheel (which is height and reach ...

Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 (Ra-223) for androgen receptor pathway inhibitor (ARPI)–naive metastatic ...

Journal of Nuclear Medicine February 2025, jnumed.124.268340; DOI: https://doi.org/10.2967/jnumed.124.268340 ...

Pomerantz LLP announces that a class action lawsuit has been filed against ESSA Pharma Inc. ("ESSA" or the "Company") and certain officers.  The class action, filed in the United States District Court ...